DRG 469 Overview

DRG 469 covers major hip and knee joint replacement procedures and reattachment of the lower extremity when a Major Complication or Comorbidity is present, and includes total ankle replacement cases that meet similar resource intensity. This Diagnosis-Related Group groups inpatient stays by high-cost orthopedic procedures with significant perioperative complexity and comorbid conditions. It matters for Medicare payment because cases assigned here drive higher Medicare Severity Diagnosis-Related Group reimbursements to reflect increased resource use, longer lengths of stay, and added care needs. Accurate clinical documentation and coding determine assignment to this Diagnosis-Related Group and associated payment.

Across commercial payers, negotiated rates for DRG 469 range widely from about $27K (UHC) up to $110K (Anthem), with most payers clustering between roughly $41K and $50K; the widest spread is between UHC at $27K and Anthem at $110K. See the table and chart below for payer-level percentiles and distributions including BCBS, Aetna, Cigna, Anthem, and UHC.

The CMS 2023 data represent national Medicare fee-for-service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($28.5k), average submitted covered charges ($138.8k), average Medicare payment amount ($24.8k), and total discharges (5.7k).

• Perioperative optimization and complication-prevention trials: These studies evaluate interventions delivered in the immediate preoperative and inpatient periods—such as enhanced prehabilitation protocols, multimodal pain control regimens, thromboprophylaxis strategies, and infection-prevention bundles—for patients undergoing major hip or knee arthroplasty or lower-extremity reattachment with major comorbidities (MCC). The population typically includes older adults with cardiovascular disease, diabetes, obesity, or renal impairment who are at higher risk for in-hospital complications and prolonged length of stay. Results matter to providers and payers because reducing perioperative complications and length of stay can directly impact resource utilization, readmission rates, and the total cost of the episode of care for this high-acuity DRG.
• Comparative effectiveness and device-outcome studies at index hospitalization: These trials compare surgical techniques, fixation methods, implant types (including total ankle replacements when appropriate), or intraoperative strategies in patients receiving major hip/knee replacement or reattachment, often stratified by severity and comorbidity burden. The research questions focus on short-term outcomes such as intraoperative blood loss, need for transfusion, immediate postoperative mobility, prosthesis alignment, and early complication rates in the inpatient period. Findings inform surgeon decision-making about approaches that balance clinical benefit and perioperative resource demands, which is critical for DRG-based reimbursement and for hospitals optimizing care pathways for patients with complex medical backgrounds.
• Post-discharge outcomes, rehabilitation, and bundle-of-care trials: These studies examine post-acute care pathways, rehabilitation intensity, transitional care models, and readmission-reduction interventions for patients discharged after major joint replacement or limb reattachment—particularly those with multiple chronic conditions who are at risk for functional decline or readmission. Typical endpoints include functional recovery trajectories, 30- to 90-day readmissions, post-acute facility utilization, and patient-reported outcomes, evaluated across different discharge destinations and care coordination models. This research is relevant to providers and payers because improvements in post-discharge management can decrease downstream utilization, improve functional outcomes, and influence total-cost-of-care metrics tied to bundled payments and DRG reimbursement models.